The U.S. Food and Drug Administration (FDA) approved the Biologics License Application for the Nuvaxovid (Novavax) COVID-19 jab in adults 65 years and older and individuals 12 through 64 with at least one underlying condition.
“Today’s approval solidifies a pathway for Americans aged 65 and older and those aged 12
Continue reading
Join the conversation!
Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!